Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Zhu, Hongwu ^a   Xia, Limin ^a   Zhang, Yongguo ^a   Wang, Honghong ^a   Xu, Wenjing ^a   Hu, Hao ^a   Wang, Jing ^a   Xin, Jing ^a   Gang, Yi ^a   Sha, Sumei ^a   Xu, Bin ^a   Fan, Daiming ^a   Nie, Yongzhan ^a   Wu, Kaichun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; HISTONE DEACETYLASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ACTIVATING TRANSCRIPTION FACTOR 4; GLYCOPROTEIN P; SIRT1 PROTEIN, HUMAN; SIRTUIN 1; TUMOR PROTEIN;

ACTIVATING TRANSCRIPTION FACTOR 4 GENE; ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PHENOTYPIC VARIATION; PROMOTER REGION; SIRT1 GENE; SITE DIRECTED MUTAGENESIS; STOMACH CANCER; TRANSACTIVATION; TUMOR GENE; TUMOR PROMOTION; UPREGULATION; APOPTOSIS; DNA DAMAGE; DOWN REGULATION; DRUG ANTAGONISM; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; STOMACH TUMOR; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 4; APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DNA DAMAGE; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; PROMOTER REGIONS, GENETIC; RNA, SMALL INTERFERING; SIRTUIN 1; STOMACH NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UP-REGULATION;

EID: 84857181300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031431     Document Type: Article

References (42)

1. Zhang D, Fan D, (2010) New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol 6: 527-537.
2. Larsen AK, Escargueil AE, Skladanowski A, (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85: 217-229.
3. Larsen AK, Skladanowski A, (1998) Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1400: 257-274.
4. Wilson TR, Longley DB, Johnston PG, (2006) Chemoresistance in solid tumours. Ann Oncol 17 (Suppl 10): x315-324.
5. Zhang D, Fan D, (2007) Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther 7: 1369-1378.
6. Lu PD, Harding HP, Ron D, (2004) Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J Cell Biol 167: 27-33.
7. Vattem KM, Wek RC, (2004) Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells. Proc Natl Acad Sci U S A 101: 11269-11274.
8. Ron D, (2002) Translational control in the endoplasmic reticulum stress response. J Clin Invest 110: 1383-1388.
9. Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I, et al. (2004) Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J 23: 169-179.
10. Rutkowski DT, Kaufman RJ, (2003) All roads lead to ATF4. Dev Cell 4: 442-444.
11. Rzymski T, Milani M, Singleton DC, Harris AL, (2009) Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8: 3838-3847.
12. Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, et al. (2009) The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Res 69: 4415-4423.
13. Fung H, Liu P, Demple B, (2007) ATF4-dependent oxidative induction of the DNA repair enzyme Ape1 counteracts arsenite cytotoxicity and suppresses arsenite-mediated mutagenesis. Mol Cell Biol 27: 8834-8847.
14. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, et al. (2007) Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26: 4749-4760.
15. Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, et al. (2003) Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 63: 8592-8595.
16. Levenson VV, Davidovich IA, Roninson IB, (2000) Pleiotropic resistance to DNA-interactive drugs is associated with increased expression of genes involved in DNA replication, repair, and stress response. Cancer Res 60: 5027-5030.
17. Rzymski T, Milani M, Pike L, Buffa F, Mellor HR, et al. (2010) Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene 29: 4424-4435.
18. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A, (2005) Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183-10187.
19. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, et al. (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373: 423-428.
20. Liang XJ, Finkel T, Shen DW, Yin JJ, Aszalos A, et al. (2008) SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 6: 1499-1506.
21. Kabra N, Li Z, Chen L, Li B, Zhang X, et al. (2009) SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 284: 18210-18217.
22. Ameri K, Harris AL, (2008) Activating transcription factor 4. Int J Biochem Cell Biol 40: 14-21.
23. Saunders LR, Verdin E, (2007) Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489-5504.
24. Haigis MC, Sinclair DA, (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253-295.
25. Luo S, Baumeister P, Yang S, Abcouwer SF, Lee AS, (2003) Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J Biol Chem 278: 37375-37385.
26. Virrey JJ, Dong D, Stiles C, Patterson JB, Pen L, et al. (2008) Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. Mol Cancer Res 6: 1268-1275.
27. Lin YS, Green MR, (1988) Interaction of a common cellular transcription factor, ATF, with regulatory elements in both E1a- and cyclic AMP-inducible promoters. Proc Natl Acad Sci U S A 85: 3396-3400.
28. Deutsch PJ, Hoeffler JP, Jameson JL, Lin JC, Habener JF, (1988) Structural determinants for transcriptional activation by cAMP-responsive DNA elements. J Biol Chem 263: 18466-18472.
29. Montminy M, (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66: 807-822.
30. Benbrook DM, Jones NC, (1994) Different binding specificities and transactivation of variant CRE's by CREB complexes. Nucleic Acids Res 22: 1463-1469.
31. Jansen E, Ayoubi TA, Meulemans SM, Van de Ven WJ, (1997) Cell type-specific protein-DNA interactions at the cAMP response elements of the prohormone convertase 1 promoter. Evidence for additional transactivators distinct from CREB/ATF family members. J Biol Chem 272: 2500-2508.
32. Olmos Y, Brosens JJ, Lam EW, (2010) Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat.
33. Matsushita N, Takami Y, Kimura M, Tachiiri S, Ishiai M, et al. (2005) Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 10: 321-332.
34. Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, et al. (2011) Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300: 197-204.
35. Hajji N, Wallenborg K, Vlachos P, Fullgrabe J, Hermanson O, et al. (2010) Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene 29: 2192-2204.
36. Oh WK, Cho KB, Hien TT, Kim TH, Kim HS, et al. (2010) Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol Pharmacol 78: 855-864.
37. Ford J, Jiang M, Milner J, (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463.
38. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, et al. (2006) Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 66: 4368-4377.
39. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, et al. (2006) Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2: e40.
40. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P, (2010) FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5054-5063.
41. Su N, Kilberg MS, (2008) C/EBP homology protein (CHOP) interacts with activating transcription factor 4 (ATF4) and negatively regulates the stress-dependent induction of the asparagine synthetase gene. J Biol Chem 283: 35106-35117.
42. Lehr HA, Mankoff DA, Corwin D, Santeusanio G, Gown AM, (1997) Application of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45: 1559-1565.